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Introduction 
Lung cancer remains one of the deadliest neoplasms 
worldwide, with less than 18% of patients alive five years 
after diagnosis (1); non-small cell lung cancer (NSCLC) 
accounts for 85% of all lung cancers (2). Notably, NSCLC 
is not a single pathological entity, but it is rather a mixture 
of malignancies different in terms of histology and 
molecular patterns, differentially impacting upon disease 
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ALK inhibitors beyond crizotinib. Clinical behaviors of ALK-rearranged NSCLC vary significantly among 
patients and differential molecular events responsible of crizotinib resistance account for the most important 
quote of this heterogeneity. The precious availability of a wide range of active anti-ALK compounds should 
be approached in a critical and careful perspective, in order to develop treatment strategies tailored on the 
disease evolution of every single patient.
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outcomes. Several genetic events lead to the expression of 
molecularly altered tyrosine kinase receptors (TKRs) and 
signaling proteins that, while conferring decisive oncogenic 
potential to malignant cells, represent suitable and crucial 
therapeutic targets. In addition to mutations occurring in 
EGFR, KRAS, BRAF and other genes (3), recent interest has 
been conferred to gene fusions determining the aberrant 
expression of proteins, which generates similar profiles of 
oncogenic addiction (4). 
Among these, the anaplastic lymphoma kinase (ALK) 
protein, encoded by the ALK gene on chromosome 2p, is 
a transmembrane TKR. ALK protein is important for fetal 
development, but its expression is lost in all adult tissues, 
with exception of the brain. Rearrangements in ALK gene 
release it from the negative control exerted by silencing 
promoters, giving rise thus far to ALK fusion transcripts 
and active proteins. The latter are the crucial and funding 
events in ALK-rearranged pathognomonic anaplastic large 
cell lymphoma (ALCL), inflammatory myofibroblastic 
tumors (IMT) and NSCLC (5). Concerning lung tumors, 
inversions within chromosome 2p are the most frequent 
genetic alterations leading to the fusion of ALK with the 
partner gene echinoderm microtubule associated protein 
like 4 (EML4) (6). Other mechanisms of gene rearrangement 
and different partner genes on different chromosomes are 
possible. The loss of ALK transmembrane domain alters its 
localization, addressing the fusion protein almost invariably 
to the cytoplasmic compartment (4). Importantly, the kinase 
domain of ALK is always conserved and constitutively 
active, transmitting mitogenic, survival and anti-apoptotic 
signals to the nucleus through intracellular pathways.
Taking into account the estimation of 224,390 new 
diagnoses of lung cancers in 2016 in USA (1) and the large 
proportion of advanced NSCLC, the absolute number of 
ALK-rearranged tumors is expected to be between 2,670 
and 10,680, considering its relative incidence of 2–8% (6-9). 
In Europe, about 410,000 new lung cancer cases are 
diagnosed every year (10): between 5,000 and 19,000 cases 
of ALK-positive advanced NSCLC are thus far expected.
Crizotinib, initially developed as a cMET inhibitor, is 
an oral inhibitor of ALK that exert its activity competing 
with ATP binding in the kinase domain of the enzyme. 
Crizotinib showed impressive response rates (RR) and 
prolonged progression-free survival (PFS) compared with 
chemotherapy in ALK-positive patients in both pretreated and 
first-line settings (11-13); PROFILE 1007, 1005 and 1014, 
respectively). This molecule is currently approved for patients 
whose tumors harbor ALK rearrangements. Unfortunately, 
almost every ALK-rearranged tumor eventually acquires 
resistance during crizotinib treatment, frequently within 
one year since the initiation of treatment (11). Mechanisms 
responsible of resistance to crizotinib include ALK mutations, 
ALK amplification and bypass of target signaling (14,15). 
Furthermore, different mutations may coexist in the same 
patient, increasing the difficulty of detecting every event 
conferring resistance to crizotinib (14). As brain is among the 
most frequent site of disease progression, pharmacokinetics 
issues concerning crizotinib ability to cross the blood-brain 
barrier have also been risen up (16). 
Second- and third-generation ALK inhibitors have 
been developed to overcome acquired crizotinib resistance. 
These novel compounds are more potent than crizotinib 
and structurally distinct. Ceritinib (LDK378) and alectinib 
(CH5424802/RO5424802) are already approved by U.S. 
Food and Drug Administration (FDA) in crizotinib-
resistant patients, while brigatinib (AP26113), lorlatinib 
(PF-06463922) and entrectinib (RXDX-101) are in different 
phases of clinical development. 
Nevertheless, some of these new compounds are 
currently compared to the first generation molecule in 
crizotinib-naive patients, in order to evaluate if an upfront 
“stronger” ALK inhibition can control the disease longer 
than the sequential treatment. Moreover, also if almost 
all patients do respond to crizotinib, primary (de novo) 
resistance actually exists (17).
The rapid and continuous development of the new-
generation ALK inhibitors requires a thorough and updated 
knowledge of their biological relevance, of their early 
and confirmed clinical activity, as long as their current 
approval and experimental status. Such availability provides 
incomparable opportunities for the treatment of ALK-
rearranged NSCLC patients. Nevertheless, the careful 
analysis of published and presented data is of crucial 
importance, as long as the design of smart clinical trials, in 
order to define the best treatment strategies. This position 
paper reviews current clinical evidence and discusses the 
development and future perspectives of recently discovered 
ALK inhibitors. 
Molecular pathology of ALK-rearranged NSCLC
ALK is a member of the insulin receptor super-family of 
receptor tyrosine kinases with unclear physiologic functions. 
In humans, ALK expression is limited to the adult brain, 
whereas no expression has been evidenced in normal lung 
tissue (18).
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EML4-ALK rearranged NSCLC harbor a chimeric 
fusion gene involving ALK. This fusion results from the 
rearrangement within chromosome 2 [inv (2)(p21p23)] and 
fusion of the 5' portion of EML4 with the 3' portion of ALK (6). 
At least 14 variants of the EML4-ALK fusion gene have been 
reported thus far, encoding for the cytoplasmic portion of 
ALK protein and containing varying lengths of EML4 (19). 
Variants v1, v2, v3a and v3b of EML4-ALK fusion gene are 
the most commonly detected, together accounting for more 
than 90% of variants in some series (20). Although more 
uncommon, other ALK fusion partners have been identified 
as TFG (TRK-fused gene), KIF5B, PTPN3 and KLC1 (21-23). 
The different EML4 variants and the further partner genes 
do not seem to significantly impact on biology and sensitivity 
of ALK-rearranged malignant cells and tumors to specific 
inhibitors (24-26) although a putative role in conditioning 
response to treatments has been reported in vitro (27).
Retrospective and prospective screenings of ALK 
in NSCLC have consistently demonstrated that ALK-
rearranged (ALK-positive) tumors are associated with 
adenocarcinoma histology, particularly when showing 
a solid, signet ring cell or mucinous cribriform pattern 
(7,28,29). In addition, ALK-positive NSCLC are associated 
with a lower age at diagnosis (median, 54 years) than that 
observed in other genetic subsets of lung adenocarcinoma, 
and never/light smoker status (6,7). ALK and ROS1 fusion-
positive tumors seem to have a significantly shorter disease-
free survival after adjusting for confounding factors (30); 
however, this does not necessarily translate into a short 
overall survival, since some patients present a favorable 
natural history of disease and may be candidate to several 
lines of therapy. ALK rearrangements in NSCLC initially 
appeared to be mutually exclusive with activation occurring 
in other oncogenic drivers (31); however, recent studies 
revealed concomitant EGFR or KRAS mutations and ALK 
rearrangements (32-34).
Testing for ALK rearrangements
Although the prevalence of tumors harboring ALK gene 
fusion is relatively low, the significant absolute number 
of patients diagnosed with NSCLC and the dramatic 
effect exerted by ALK inhibitors on disease courses make 
the identification of ALK-positive patients crucial (35). 
Albeit the screening for ALK-positive tumors in clinical 
trials with ALK inhibitors was based on fluorescence in 
situ hybridization (FISH) assay, the identification of ALK 
rearrangements may be performed by other diagnostic 
approaches, including immunohistochemistry (IHC) and 
reverse transcriptase-polymerase chain reaction (RT-
PCR) (36). Beyond these more “traditional” techniques, 
the applicability of next-generation sequencing (NGS) 
technologies to the detection of gene fusions and their 
current widespread availability deserve mention. Diagnostic 
algorithms emerging from the integration of the cited 
analysis should lead to standardized procedures. The 
latters aim therefore to combine sensitivity and specificity, 
to generate reproducible data and to allow the best 
management of tumor tissue, always precious in lung 
malignancies, as frequently derived from small biopsies or 
cytological samples. 
FISH
ALK FISH analysis relies on a break-apart probe 
provided with two fluorochromes, respectively labeling 
the 3' (telomeric) and 5' (centromeric) parts of the fusion 
breakpoint (Vysis LSI ALK dual-color, break-apart probe, 
Abbott Laboratories, Abbott Park, IL, USA). Superimposed 
signals indicate ALK wild-type status, while inversion and 
rearrangements generate signals that can be identified as 
split or isolated (36). This technique works appropriately 
either on archival paraffin-embedded tumor specimens and 
well-prepared, mono-layer, non-bloody smeared cytology 
(37,38). A cut-off of >15% rearranged tumor cells, counting 
at least 50 tumor cell nuclei, has been decided to quote ALK 
fusions by FISH (Figure 1) (26). As already stated, ALK 
rearrangement is the key mechanism of transformation 
and oncogenesis: virtually all cells therefore harbor at least 
one rearranged copy of the ALK gene. The threshold of 
15% is thus far technique-dependent and it is not driven 
by tumor biology (39). This cut-off revealed as the best 
option to couple specificity (ALK positive cells can appear 
FISH negative due to nuclear chromatin status) and 
sensitivity (ALK negative cells can appear FISH positive 
because of stochastic and isolated genomic alterations or 
artifact) (36,39). Due to the lack of clear-cut discrimination 
nature of the cut-off >15%, rates comprised between 10% 
and 15%, occurring in the 8.5% of NSCLC (40), require 
a critical approach. In these specific cases more than in 
others, re-performing FISH analysis and addressing to 
further techniques of detection (see below) is necessary in 
order to “catch” every single NSCLC patient with true 
ALK rearrangements. 
As mentioned, inversion in the chromosome 2p are 
the most frequent event leading to EML4-ALK fusions; 
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Figure 1 Different ALK staining expression at IHC with clone 5A4 (A) and Ventana D5F3 CD assay (B). Insert in image (A) shows the ALK 
positivity in signet ring tumor cells with a thin rim of brownish-stained cytoplasm dislocated under the nuclear membrane. FISH analysis 
showing tumor cells with normal ALK set-up with one normal fusion signal and one single red/orange signal (C); ALK positivity by gene 
deletion with single 3' orange rearranged signals (deleted green signal) (D, arrowheads) and ALK positivity by inversion with “broken apart” 
signals, 2 or more signal diameters apart (E, arrows). IHC, immunohistochemistry; ALK, anaplastic lymphoma kinase; FISH, fluorescence 
in situ hybridization.
this occurrence implies that the breakpoint in ALK gene 
generate a small physical separation between the 3' and 
5' extremities, sometimes making the “break apart” 
challenging to identify (41).
Moreover, interpretation of FISH results can be very 
challenging, as it requires great expertise to interpret 
fluorescence microscope images when only a subset of 
tumor cells may be evaluable for split assessments. Another 
major issue with FISH derives from the correct recognition 
of tumor cells in dark-field microscopy among inflammatory 
and stromal cells or normal bronchus-associated salivary 
glands that may lead to false-negatives or false-positives 
results (36). FISH is also labor intensive and costly when 
adopted as a screening tool for thousands of patients (42).
IHC
Since ALK protein is not expressed in normal tissues, IHC 
demonstrating ALK expression is an alternative approach 
that enables analysis of paraffin-embedded tumor specimens 
in clinical practice. IHC is a routine procedure and well-
known ancillary method in all pathology settings, is less 
labor intensive and more cost-effective than FISH, permits 
the identification of tumor cells at light morphology and 
therefore results as a good screening test (43). There is a 
consistent body of evidence demonstrating that IHC is 
comparable, if not superior, to FISH (44,45). In a recent 
study (46), the sensitivity and specificity were 43% and 98% 
for FISH and 100% and 98% for IHC, respectively. Relevant 
discrepancies between FISH and IHC results have indeed 
been reported (47-49). Importantly, patients responding 
to ALK inhibitors with an ALK IHC-positive but FISH-
negative adenocarcinoma have been extensively described 
(49,50). The main issue with IHC is that ALK protein in ALK-
rearranged lung NSCLC is restricted in the cytoplasm with/
without membrane staining and it is expressed at lower level 
A B C
D
E
100 μm 100 μm
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than those pathologists are used to observe in ALCL, where 
the t(2;5) translocation generates the nucleophosmin (NPM)-
ALK fusion gene, leading to strong nuclear and cytoplasmic 
immunostaining with ALK antibody (51). There are at least 
four different commercially-available clones with different 
sensitivities, namely ALK1, 5A4, 1A4 and D5F3. Comparison 
studies have not evidenced any significant difference 
among them in detecting ALK-positive NSCLC (52). 
However, staining intensity may be quite different and 
intercalated antibody-enhanced polymer methods or 
amplification kits have been used to improve the sensitivity. 
ALK1 clone indeed, useful in addressing molecular 
diagnosis in ALCL and provided of good specificity, lacks of 
appropriate sensibility in NSCLC, due to the aforementioned 
lower expression of ALK transcripts (53). 
While FDA approved the use of ALK inhibitor crizotinib 
employing the companion diagnostic Vysis probe for FISH, 
the EMA required the demonstration of ALK-positive 
status by any appropriate method, not only by FISH (43). 
Recently, both the FDA (June 2015) and the Italian Drug 
Agency (Agenzia Italiana del Farmaco, AIFA) (April 2015) 
approved the selection of ALK-positive NSCLC using 
IHC. While the FDA opened to IHC identification of 
ALK-positive patients only with Ventana (Ventana Medical 
Systems, Inc., Tucson, AZ, USA) ALK (D5F3) companion 
diagnostic assay (54), AIFA permitted the use of various 
clones adopting basic and clear rules based on the scoring 
staining and the antibody clone (Figure 2). D5F3 and 5A4 
with an appropriate highly sensitive amplification kit are the 
best clones when using a platform different from Ventana/
Roche, while the Ventana/Roche CDx D5F3 is the most 
adequate IHC system when a Ventana/Roche platform is 
available in the own lab (49). The possibility to have a dual 
ALK IHC/in-situ hybridization assay is realistic and appears 
promising (55,56). 
Reverse transcriptase-polymerase chain reaction (RT-PCR)
RT-PCR represents a valuable tool to detect ALK 
rearrangements in NSCLC (57). However, the high quality 
of RNA required by this analysis, not always provided by 
formalin-fixed, paraffin-embedded (FFPE) specimens, 
make the clinical applicability challenging. Most of the 
current guidelines do not include it ALK RT-PCR in their 
diagnostic algorithms, as the rate of failures and false-
negative tests can be significant. Nevertheless, RT-PCR 
can find its best utility in samples not suitable for tissue 
blocking, mainly represented by bronchial washing fluid and 
pleural effusions (19,58). RT-PCR could represent a useful 
tool to detect fusion variants of the EML4-ALK fusion 
gene which otherwise, besides harboring unclear clinical 
significance (see above), can be currently revealed by next-
generation genomic and transcriptomic analyses (see next 
paragraph). 
Figure 2 AIFA-based scheme in detecting ALK-positive NSCLC using an integrated approach with IHC and FISH. All antibody clones 
against ALK are accepted employing a scoring system, then requiring FISH confirmation in indeterminate cases at IHC (scores 1+ and 2+). 
AIFA, Agenzia Italiana del Farmaco; ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; IHC, immunohistochemistry; 
FISH, fluorescence in situ hybridization.
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Next-generation techniques 
The current or upcoming diffuse possibility to perform 
deep genomic analysis on both DNA (targeted NGS, whole 
exome sequencing, comparative genomic hybridization) and 
RNA (RNA sequencing) allow to obtaining large amounts 
of information from a single specimen (59). Focusing on 
relevant fusions in NSCLC, molecular events involving ALK, 
ROS1, RET and NTRK1-3 genes would hopefully, in the 
next future, routinely been simultaneously sounded out (60), 
allowing the exploitation of small amounts of material. 
Moreover, deep sequencing analysis can be performed on 
FFPE samples and not necessarily on frozen tissues (61). 
With special regard to ALK rearrangement, NGS feasibility 
and reliability have been already proven (46). 
Differently from FISH and IHC (and with overall better 
performances than RT-PCR), NGS analysis can provide 
information concerning ALK fusion partner gene and, in 
the most of the cases, the involved variant of EML4 gene. 
A similar scenario is depicted for rearrangements involving 
ROS1, which is strictly related, for phylogenetic and 
oncogenic homologies, to ALK (62). 
The issue of acquired resistance to crizotinib
Once ALK rearrangements are detected in NSCLC 
patients, crizotinib can be usefully administered as front-
line treatment (13) or after chemotherapy (11). Irrespective 
of the line of treatment, crizotinib exhaustion manifests 
after a median period of 7.7 to 10.9 months (11,13,63). 
As observed in other oncogene-addicted tumors such as 
EGFR-driven NSCLC, acquired resistance to crizotinib 
almost invariably emerges and leads to clinical progression. 
Resistance to crizotinib derives from different 
mechanisms, that include ALK secondary mutations in 
approximately 20% to 40% of patients: the L1196M 
(gatekeeper) and G1269A are the more frequent, while the 
1151T-ins, L1152R, C1156Y, F1174C/V, G1202R, D1203N, 
1206Y and G1269A are less often observed (13,14,64-66). 
Moreover, the current availability of NGS methods 
allows the detection of further rare mutations in ALK 
kinase domain conferring either crizotinib sensitivity (67) 
or resistance, while allowing the inhibition exerted by 
second-generation inhibitors (68).
Amplification of rearranged ALK gene is reported in 
approximately 15% of crizotinib-refractory patients (14), 
while activation of EGFR, KRAS, c-KIT or IGF-1R 
signaling is reported in up to 30% of patients (14,15,69). 
Depending of the case series, the mechanisms underlying 
acquired resistance to crizotinib remain unknown in 
approximately 50% of patients. 
The virtually inevitable occurrence of biological 
resistance to crizotinib accelerated, in the recent past years, 
the development of new ALK inhibitors provided with 
pharmacodynamics and pharmacokinetics improvements, 
whose best integration in treatment strategies is of pivotal 
interest.
Development program of new ALK inhibitors
Among second-generation ALK inhibitors, ceritinib 
received FDA and EMA approvals  in  Apri l  2014 
and in May 2015 respectively, in the setting of ALK-
positive NSCLC patients showing crizotinib resistance 
or intolerance. Alectinib, available in Japan since July 
2014, received FDA approval in December 2015 and is 
currently under evaluation by EMA. Brigatinib received 
FDA granted breakthrough-therapy designation for 
ALK-positive advanced NSCLC that have progressed to 
crizotinib. Lorlatinib and entrectinib, in less-advanced 
clinical development, are promising drugs belonging to 
this category. Table 1 resumes the activity of registered and 
experimental ALK-inhibitors driven from clinical trials. 
Ceritinib
Ceritinib is 20 times more potent than crizotinib against native 
ALK protein, as shown in enzymatic assays (80), and is capable 
of reconverting crizotinib resistance in cellular functional 
studies (66). Its intrinsic potency and chemical structure allow 
its interference with ATP within ALK kinase domains that 
have undergone several of the cited mutations (66). 
In crizotinib-naive ALK-positive patients treated with 
ceritinib in the phase I ASCEND-1 trial, the overall RR 
was 62% when treated with at least 400 mg daily; 21/34 
patients reported a partial response. In the same subgroup 
of patients, the median PFS was 10.4 months, with 
18 patients (53%) censored and a median follow-up of 
9.5 months (81). In the same study, 83 ALK-positive 
NSCLC patients who had progressed under crizotinib were 
enrolled in the dose-escalation or phases. Among them, 
the ORR was of 56% and median PFS was 6.9 months. 
Importantly, all the 19 cases for whom tumor material was 
available at crizotinib progression responded to ceritinib, 
regardless of the respective mechanism of acquired 
resistance, also when the precise molecular explanation 
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was not uncovered (81). The updated analysis of this trial 
at median duration of follow-up of 11.1 months, showed 
a median PFS of 18.4 and of 6.9 months in ALK inhibitor 
naive and pre-treated patients that received ceritinib at the 
recommended 750 mg/day dose (70). 
In patients with chemotherapy and crizotinib-refractory 
ALK-positive NSCLC, a phase II trial with ceritinib at 
the dose of 750 mg daily was conducted (ASCEND-2; 
Clinicaltrials.gov identifier: NCT01685060) enrolling a 
total of 140 patients (71). Patients should have received 
cytotoxic therapy (1–3 lines, including 1 platinum doublet) 
and progressed on crizotinib as the last treatment prior 
to study entry. The overall response rate (ORR) by 
investigators was 38.6% (35.7% by blinded independent 
review committee), with a PFS of 5.7 months.
ASCEND 3 (Clinicaltrials.gov identifier: NCT01685138) 
is a one-arm, phase II trial in 124 ALK-positive NSCLC 
patients who had not received prior treatment with ALK 
inhibitors (98.4% had received at least 1 line of prior 
chemotherapy and 25% of patients had received ≥3 prior 
antineoplastic regimens) (72). The study met its primary 
end-point, with a whole-body ORR of 63.7% (by blinded 
independent review committee of 58.9%); responses were 
durable, leading to a median PFS of 11.1 months with a 
median follow-up of 8.3 months (72). 
The results of two phase III trials comparing ceritinib 
with standard chemotherapy are awaited. In ASCEND 
4 (Clinicaltrials.gov identifier: NCT01828099) patients 
suffering by ALK-positive advanced NSCLC, not 
previously exposed to crizotinib, are randomized to receive 
a first line chemotherapy with platinum-pemetrexed or 
ceritinib. In ASCEND-5 (Clinicaltrials.gov identifier: 
NCT01828112) patients progressing after crizotinib and 
chemotherapy are randomized to receive either a cytotoxic 
treatment with pemetrexed or docetaxel (per investigator 
choice) or ceritinib. 
A recent retrospective multicenter analysis estimated 
at 17.4 months the median combined PFS to sequential 
crizotinib and ceritinib treatment in 73 ALK-positive 
patients (82). Considering the results obtained by ceritinib 
in crizotinib-naïve patients (70), current trials evaluating 
ceritinib treatment in ALK-TKI-naive patients (ASCEND 
3 and 4) should aim to confirm the latter data and to 
reach a comprehensive duration of disease control at least 
Table 1 Activity of ALK-inhibitors emerged from completed and ongoing clinical trials.
Drug Study (reference)
Previous crizotinib Crizotinib-naive
ORR mPFS (months) ORR mPFS (months)
Crizotinib Phase I (63) (PROFILE 1001) 87/143 (60.8%) 9.7
Phase II (12) (PROFILE 1005) 155/259 (59.8%) 8.1
Phase III 2nd line (11) (PROFILE 1007) 113/173 (65%) 7.7
Phase III 1st line (13) (PROFILE 1014) 128/172 (74%) 10.9
Ceritinib (LDK378) Phase I (70) (ASCEND-1) 92/163 (56%) 6.9 60/83
72%
18.4
Phase II (71) (ASCEND-2) 54/140 (38.6%) 5.7
Phase II (72) (ASCEND-3) 79/124 (63.7%) 11.1
Alectinib  
(CH542480/RO5424802)
Phase I/II (73) (AF-001JP), 240/300 mg BID 58/61 (95%) NA
Phase I/II (74), dose escalation (AF-002JG) 24/44 (55%) NA
Phase II (75) (NP28761) 33/69 (48%) NA
Phase II (76) (NP28673) 61/122 (50%) 10.3
Brigatinib (AP26113) Phase I/II (77), phase II portion 
(NCT01449461)
50/70 (71%) 13.4 8/8 (100%) Not reached
Lorlatinib (PF-06463922) Phase I/II (78), dose escalation 
(NCT01970865)
17/32 (53.1%) NA 2/2 (100%) NA
Entrectinib (RXDX-101 ) Phase I/II (79), dose escalation 
(NCT02097810 )
2/4 (50%) NA
ALK, anaplastic lymphoma kinase; ORR, objective response rate; mPFS, median progression-free survival; NA, not available.
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overlapping with the one reported with two compounds in 
sequential treatment. 
Although preclinical and clinical research mainly focuses 
on acquired resistance to crizotinib, absolute lack of response 
to the inhibitor can be distinctly observed in 5% to 7% of 
ALK-positive patients (11,13,63). Albeit most of the primary 
resistance cases can be attributed to misdiagnoses of ALK-
rearrangements (48), “true” biological de novo resistance 
can be driven by co-occurring K-RAS mutations (83) or by 
unknown mechanisms (17). Although the eventual role of 
ceritinib in the first scenario is not clear, its intrinsic greater 
potency can explicate the complete inhibition of ALK 
signaling when the second circumstances occur (17). 
Alectinib
Alectinib is a potent and selective ALK inhibitor (84). The 
initial phase I dose-escalation portion of the Japanese AF-
001JP study included 24 crizotinib-naive patients with 
recurrent/relapsed ALK-positive NSCLC. Alectinib was 
administered at doses ranging from 20 to 300 mg twice daily. 
In the phase II portion of the trial, 46 ALK inhibitor-naïve 
patients were treated with 300 mg twice daily of alectinib. 
This drug displayed an excellent RR in both moments of 
the study (93.5% in the phase II cohort), with long response 
durations and an acceptable toxicity profile (73). Two 
complete responses and 41 partial responses were achieved 
among the 46 evaluable patients, and the two-year PFS rate 
was 76%. Published data were too early to deduce robust 
information concerning median PFS in the phase II portion 
with the recommended posology of alectinib; with a median 
follow-up of 12 months, the mean duration of treatment was 
11.8 months within the escalation-dose phase (73).
Alectinib demonstrated promising antitumor activity 
also in patients with ALK-rearranged NSCLC resistant 
to crizotinib, including those with central nervous system 
(CNS) metastases. In the dose-finding portion of the AF-
002JG trial, a phase I/II study performed in the United 
States in ALK-positive NSCLC patients previously treated 
with crizotinib, alectinib allowed a RR of 55% (74). In 
a global phase II study testing alectinib in crizotinib-
refractory ALK-rearranged NSCLC (NP28673), the RR 
was 50% in the whole study population (including both 
patients pretreated with chemotherapy and chemotherapy-
naive) and 45% in the subgroup of patients pretreated with 
chemotherapy (76). In an ongoing phase II study enrolling 
87 ALK-positive patients who had progressed on crizotinib 
(NP28761), at the time of the primary analysis (median 
follow-up 4.8 months), 33 out of 69 patients (48%) with 
measurable disease at baseline had a confirmed partial 
response with alectinib (75). 
On the basis of these results, ALEX, a phase III 
randomized trial, has been initiated to compare alectinib 
with crizotinib in treatment-naïve, ALK-positive, 
advanced NSCLC patients (ClinicalTrials.gov identifier 
NCT02075840). 
Importantly, during the final preparation of this 
manuscript, the study sponsor of ALEX trial released a 
press communication reporting that among a Japanese 
population of ALK-rearranged NSCLC patients, the front-
line administration of alectinib versus crizotinib achieved 
an impressive benefit in mPFS, quantified with a Hazard 
Ratio of 0.34 (85). The anticipated outstanding activity of 
alectinib will be extensively presented at the upcoming 2016 
ASCO meeting (Abstract #9008).
Brigatinib
Brigatinib is a tyrosine kinase inhibitor that showed 
preclinical activity against ALK and 9 clinically-identified 
crizotinib-resistant mutants (86,87). Moreover, this 
compound exerts in vitro activity against both ALK and 
EGFR (88), making it a suitable therapeutic option for 
patients progressing to crizotinib with activation of EGFR 
pathway as the mechanism of resistance (14,15,66). Indeed, 
in an ongoing phase I/II study of brigatinib both in ALK-
rearranged and EGFR-mutated NSCLC patients, brigatinib 
is demonstrating significant antitumor activity in ALK-
positive NSCLC patients with and without prior crizotinib, 
including patients with brain metastases. After the dose-
escalating portion of the study, patients were divided into 
three cohorts that received 90, 90–180  (escalating after 
7 days) or 180 mg of the drug daily (77,89). According to the 
latest updates concerning those 78 evaluable ALK-positive 
NSCLC patients treated in the phase II portion of the study, 
50 (71%) responded: 50/70 (71%) pretreated with crizotinib 
and 8/8 crizotinib-naive patients (with three complete 
responses in this last sub-cohort) (77). The overall median 
PFS was not reached in the crizotinib-naive sub-group and 
corresponded to 13.4 months in patients already exposed to 
crizotinib; one-year OS rates were 100% and 81% for the 
two just mentioned population, respectively (77). 
The pivotal phase II ALTA (ALK in Lung cancer Trial 
of AP26113) trial in patients with ALK-positive NSCLC 
patients pretreated with crizotinib has recently terminated 
enrolment (ClinicalTrials.gov identifier: NCT02094573) 
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and primary outcome evaluations are expected in November 
2016. As reported for ceritinib and alectinib, a head-to-
head comparison of crizotinib versus brigatinib will soon 
begin (ClinicalTrials.gov identifier: NCT02737501; ALTA-
1L trial). Finally and interestingly, brigatinib will be soon 
evaluated after the exhaustion of other second-generation 
ALK-inhibitors (namely ceritinib or alectinib) in a phase 
II study (ClinicalTrials.gov identifier: NCT02706626). 
It would be noteworthy to assess the clinical response to 
this compounds in patients affected by tumors harboring 
G1202R and I1171N/S/T mutations, not overcome by 
ceritinib and alectinib respectively (66,90,91).
Lorlatinib
Lorlatinib is an extremely selective and potent third-
generation ALK/ROS1 inhibitor, with sub-nanomolar 
activity against EML4-ALK enzyme and almost all its 
mutant forms, including the ones driving resistance to 
ceritinib and alectinib (92,93). Preclinical activity in 
cellular assays and in mouse models (93) have been recently 
confirmed in the dose-escalation portion on a phase I/II 
study (78). Recommended phase II dose was set at 100 mg 
once daily. Among the 43 ALK/ROS1-positive NSCLC 
patients evaluable for radiological responses, one complete 
and 19 partial response were observed, with seven, 14 and 
two cases accounting for disease stability, progression and 
indeterminate response, respectively (78). Treatment efficacy 
was observed regardless of the number of prior specific 
inhibitors assumption; lorlatinib confirmed clinical activity 
also against G1202R mutation, which confers the highest 
degree of resistance to both crizotinib and ceritinib (66). 
As described for EGFR-mutated NSCLC, progressing 
to the third-generation inhibitor AZD9291 because of the 
emergence of C797S mutation, sensible to first-generation 
compounds (94), ALK substitution L1198F drives resistance 
to ceritinib, alectinib, brigatinib and lorlatinib, while re-
sensitizing tumor cells to crizotinib (95). 
Entrectinib
Entrectinib, initially envisaged as an ALK inhibitor (96), 
currently represents the best antagonist of NTRK1-3 
fusion proteins, an emerging reality in oncogenic-driven 
NSCLC (97), while expressing activity against ROS1-
rearranged cancer cells too (98). Concerning specific ALK 
inhibition, entrectinib has shown remarkable in vitro and 
in vivo activity in preclinical models also against L1196M 
and CC1156Y crizotinib-resistance mutations (99). Patients 
affected by a wide range of tumor histologies harboring 
the cited fusion oncogenes were treated with entrectinib in 
two different cohorts (the Italian ALKA-372-001 and the 
international STARTRK-1), flowing into the same phase 
I study (ClinicalTrials.gov identifier: NCT02097810). 
Updated data of the study were recently presented (79); 
the recommended phase II dose was defined as 600 mg 
once daily in a continuous schedule. Among the 24 patients 
who had not previously undergone specific targeted 
inhibition and who were evaluable for treatment response, 
four suffered from ALK-rearranged NSCLC; in this small 
sub-cohort, two partial responses according to RECIST 
criteria were observed. Lack of previous specific molecular 
therapy is a main inclusion criteria in the STARTRK-2 trial 
(ClinicalTrials.gov identifier: NCT02568267), a phase II 
basket trial currently addressing to entrectinib treatment 
patients screened, by means of NGS techniques, for NTRK, 
ROS1 and ALK gene rearrangements.
Efficacy of ALK inhibitors on brain metastases
ALK-positive NSCLC are associated with a relevant 
incidence of CNS metastases, affecting approximately 35–
50% of patients (11,81,100). It is actually not clear whether 
ALK-positive patients have an increased risk of developing 
CNS metastases independently from therapy received (as an 
expression of the natural disease course) or if this higher risk 
may be related to treatment with ALK inhibitors. In fact, 
high tumor activity of these compounds with prolonged 
control of extra-cranial disease could make emerge CNS 
as relevant site of progression. This is particularly true 
for crizotinib, which may inefficiently cross the blood 
brain barrier thus reaching limited concentration in the 
cerebrospinal fluid (CSF) (16,101,102). CNS involvement 
resulted the first site of progression in 46% of ALK-positive 
patients treated with crizotinib, with 85% of these lacking 
systemic progression (103).
A retrospective analysis of crizotinib-treated patients 
enrolled in the PROFILE 1005 (12) and 1007 (11) trials 
found that 20% of patients without brain metastases at the 
time of therapy initiation subsequently experienced brain 
progression; in patients with known brain metastases, CNS 
was site of progression in 70% of cases (104). Therefore, 
in ALK-positive patients CNS represents a frequent site of 
disease and the main site of progression during crizotinib. 
Although CSF concentrations of crizotinib are modest, 
this agent is associated with intracranial disease control 
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in TKI-naïve ALK-positive patients (104-106). The 
intracranial activity of crizotinib and chemotherapy in ALK-
positive NSCLC patients included in PROFILE 1014, not 
exposed to systemic therapy but who had already undergone 
radiotherapy for brain disease, have been recently and 
comprehensively reported (107). Crizotinib administration 
allowed an intracranial disease control rate (IDCR) in 85% 
and 56% at 12 and 24 weeks, respectively (33 and 22 out of 
39 patients, respectively); in the chemotherapy arm IDCR 
was achieved in 18 (45%) out of 40 patients at 12 weeks and 
maintained in 10 (25%) at 24 weeks.
According to the National Comprehensive Cancer 
Network (NCCN) guidelines, radiotherapy to cerebral sites 
of progression, in association with crizotinib continuation, 
represents an accepted treatment strategy (108). Although 
no randomized studies are available, when ALK-positive 
patients with isolated CNS progression on TKIs received 
brain radiotherapy without crizotinib withdrawal, further 
progression occurred approximately 12 months after the 
initiation of this strategy (109). 
The greatest promise in the treatment of ALK-positive 
NSCLC patients with CNS involvement comes from new 
ALK inhibitors, expressly ceritinib, alectinib, brigatinib and 
lorlatinib. All these new agents showed promising activity 
against CNS metastases (Table 2), both in TKI-naive and in 
crizotinib-progressing patients. The improved CNS activity 
likely reflects the higher potency in ALK inhibition and 
improved CNS penetration (93). Although these studies 
were not specifically designed to evaluate patients with 
brain metastases, there is now enough evidence to support 
the use of these agents in clinical practice and, potentially, 
to delay of brain radiotherapy in favor of a further novel 
ALK inhibitor in case of asymptomatic brain lesions. 
Regarding the activity of ceritinib in CNS disease, 
patients with controlled or asymptomatic brain metastases 
were eligible in the ASCEND-1 trial (70,81). Of 124 ALK-
positive NSCLC patients with brain metastases at baseline, 
94 had brain scans evaluated by central review. In ALK-
TKI naive (n=19) and ALK-TKI pre-treated patients (n=75), 
disease-control rate (DCR) was 79% and 65%, respectively; 
whole body disease-control rate and duration were similar 
to what observed in the overall population (70). The median 
time required to achieve intracranial responses (6.1 weeks) 
overlapped with what observed for extracranial disease. 
Table 2 Activity of ALK inhibitors on brain metastases
Drug Study (reference)
Pts with brain 
mts/total treated
Pts with 
previous RT
iORR iDCR
Untreated 
brain mts1
Treated 
brain mts2
Untreated 
brain mts1
Treated  
brain mts2
Crizotinib Phase II–III (104) (PROFILE 1005–1007) 275/888 166 18% 33% 56% 62%
Phase III (107) (PROFILE 1014) 39/172 39 NA 12-w: 85%;  
24-w: 56%
Ceritinib 
(LDK378),  
750 mg/die
Phase I (70) (ASCEND-1) 124/246 83 63%# 36%# 79%* 65%*
Phase II (71) (ASCEND-2) 100/140 72 39% by IRC 85% by IRC
Phase II (72) (ASCEND-3) 50/124 27 59% by IRC 82% by IRC
Alectinib 
(CH542480/
RO5424802)
Phase I/II (74), dose escalation  
(AF-002JG)
21/47 17 75%* by 
IRC
47%* by 
IRC
100%* by 
IRC
88% by  
IRC
Phase II (75) (NP28761) 52/87 34 67%* 26.5%* 94.5%* NA
Phase II (76) (NP28673) 84/138 61 52%* 39%* 74%* 87%*
Brigatinib (88) 
(AP26113)
Phase I/II, phase II portion  
(NCT01449461)
52/79 27 52%* 28%* 88%*
Lorlatinib  
(PF-06463922)
Phase I/II (78), dose escalation 
(NCT01970865)
30Φ/50 NA 33%Φ,* 63%Φ,*
1, untreated brain metastasis: in case of ceritinib, data are relative to ALK-TKI naive patients; in other drugs are relative to no previous 
brain RT; 2, treated brain metastasis: in case of ceritinib, data are relative to ALK-TKI pre-treated patients; in other drugs are relative to 
previous brain RT; #, considering 36 patients with measurable disease; *, considering patients with measurable and non-measurable 
CNS disease; Φ, including ALK- and ROS1-positive patients. ALK, anaplastic lymphoma kinase; Pts, patients; mts, metastases; RT, brain 
radiotherapy; iORR, intracranial objective response rate; iDCR, intracranial disease control rate; NA, not available; 12-w, at 12 weeks;  
24-w, at 24 weeks; IRC, independent review committee. 
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23 patients (67%) had previously received radiotherapy to 
the brain; no difference in brain responses was observed 
between patients who had undergone or nor radiotherapy 
before ceritinib administration. Thirty-six patients (eight 
TKI-naive and 28 previously exposed to crizotinib) had 
measurable brain metastases: among them, intracranial 
ORR was 63% and 36% in naïve and pre-treated patients, 
respectively. The median ceritinib exposure was 49.6 weeks 
in ALK-TKI-naïve patients and 40.6 weeks in pre-treated 
patients. 
The ASCEND-2 preliminary results support those 
reported for previously ALK inhibitor-treated patients 
in ASCEND-1 trial (71). Among patients with brain 
metastases at study entry, 20 had investigator-assessed brain 
lesions selected as target lesions at baseline, for whom 
ORR and DCR was 45% and 80%, respectively. According 
to the Independent Review Committee, 33 patients had 
brain lesions selected as target lesions at baseline, for 
whom ORR and DCR were 39% and 85%, respectively. 
In the ASCEND-3 trial, 124 patients with ALK-positive 
NSCLC who had not received prior treatment with ALK 
inhibitor were enrolled (72). Among subjects with brain 
metastases at study entry, 10 patients had investigator-
assessed brain lesions selected as target lesions at baseline, 
for whom intracranial ORR (iORR) and iDCR were 20% 
and 80%, respectively. According to the independent review 
committee, 17 patients had brain lesions selected as target 
lesions at baseline; ORR and DCR were 59% and 82%, 
respectively. An international prospective phase II open-
label study evaluating the antitumor activity of ceritinib in 
patients with ALK-positive NSCLC metastatic to the brain 
or leptomeninges is ongoing (ASCEND-7, ClinicalTrials.
gov identifier: NCT02336451). 
Initial data concerning intracranial activity of alectinib 
derived from a phase I/II trial enrolling patients who 
progressed on or were intolerant to crizotinib (74). Among 
the 21 patients with CNS metastases at baseline treated in 
the dose-escalation portion of the study, 11 (52%) achieved 
a brain objective response (6 complete and 5 partial 
responses) and eight (38%) patients had stable disease; brain 
responses were observed at different drug doses. Results of a 
phase II trial carried out in USA were recently published; 87 
patients were enrolled and treated with alectinib at 600 mg 
twice daily (75). In patients with baseline-measurable CNS 
disease (n=16), ORR and DCR stated by an independent 
review committee were 75% and 100%, respectively, with 
notably four complete intracranial responses. When both 
patients with baseline-measurable and non-measurable CNS 
disease were included (n=52), ORR and DCR were 40% and 
89%, respectively. 
At the 2015 ASCO meeting, updated data of the 46 
crizotinib-naive patients enrolled in the phase II part of 
Japanese trial AF-001JP were presented (73,110). At a 
median follow-up >30 months, Ohe et al. showed that seven 
out of 14 patients with baseline brain metastases were still 
in the study without CNS or systemic progression; PFS 
of patients with or without brain metastases was similar. 
Moreover, in the recently published phase II NP28763 
trial (76), among the 84 crizotinib-resistant patients with 
baseline CNS metastases, 23 patients obtained a CNS 
complete response (27%); the overall intracranial DCR was 
83% and the median duration of CNS response was 10.3 
months. Considering only the 35 patients with measurable 
brain lesions at baseline, CNS objective RR was 57%, 
including achievement of seven CNS complete responses. 
High RR and DCR were confirmed also stratifying patients 
according to previous radiotherapy. At the 2015 World 
Conference on Lung Cancer, a pooled analysis of CNS 
data from two phase II multicenter studies on patients 
previously treated with crizotinib (NP28761, NP28673) 
showed a complete RR of 22%, an ORR of 39% and a DCR 
of 85% in patients with CNS disease, irrespective of prior 
radiotherapy (111). The CNS response was sustained for a 
duration similar to the systemic response, suggesting that 
alectinib could provide an effective treatment for patients 
with ALK-positive NSCLC while actively targeting CNS 
metastases.
In the phase II portion of an ongoing trial of brigatinib, 
46 out of 50 patients with intracranial metastases were 
evaluable (77). The 8/15 (53%) patients with measurable 
disease had a brain response and 11/31 (35%) patients with 
only non-measurable lesions showed disappearance of all 
lesions. Brigatinib treatment leads to a median intracranial 
PFS of 15.6 months in the 46 evaluable patients (77).
Lorlatinib shown impressive activity results in mouse 
models of CNS metastases from NSCLC tumor cells 
harboring EML4-ALK gene fusion, with or without the 
gatekeeper L1196M mutation (93). Preclinical data were 
confirmed by recent reports (78) testifying an intracranial 
disease control in 19 out of 30 ALK/ROS1-positive 
evaluable patients, who had previously undergone systemic 
treatments with at least one ALK inhibitor. Four complete 
and six CNS partial responses were observed, with one 
leptomeningeal disease resolution obtained after sequential 
crizotinib, ceritinib and alectinib administration (78).
For future clinical trials with new ALK-TKIs, it will be 
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important to consider dedicated cohorts with CNS disease 
and to focus on patients with previously not irradiated brain 
metastases or those with brain metastases progressing after 
irradiation. 
Safety profile of ALK inhibitors
The wide majority of available data concerning safety of 
second-generation ALK inhibitors have been obtained 
within studies including patients, who had already 
undergone crizotinib treatment (Table 3). Thus, the 
populations analyzed for safety are mixed and many data 
derive from phase I studies or their expansions cohorts. 
Anyway, ALK inhibitors are globally characterized by very 
good safety and tolerability profiles, without real substantial 
differences among compounds, combining thus far 
significant activity with the lack of frequent relevant adverse 
events.
Table 3 Safety profile of ALK inhibitors
Drug Study Grade 3–4 toxicities
Most common all-grade 
adverse event
Crizotinib Phase I (63) (PROFILE-1001),  
149 patients
ALT: 6 pts (4%); AST: 5 pts (3%) Visual disorders: 96 pts 
(64%)
Phase II (12) (PROFILE-1005), 
901 patients
Neutropenia: 72 pts (8%); ALT: 55 pts (6.1%); fatigue: 22 pts 
(2.5%)
Visual disorders: 571 pts 
(63.3%)
Phase III (11) (PROFILE-1007), 
173 patients
ALT/AST: 27 pts (16%);  
dyspnea: (7 patients, 4%)
Visual disorders: 103 pts 
(60%)
Phase III (13) (PROFILE-1014), 
172 patients
ALT/AST: 24 pts (14%) Visual disorders: 122 pts 
(71%)
Ceritinib  
(LDK378),  
750 mg/die
Phase I (70) (ASCEND-1),  
255 patients
ALT: 73 pts (30%); AST: 25 pts (10%);  
diarrhea: 15 pts (6%); nausea: 15 pts (6%);  
lipase: 16 pts (6%); hyperglycaemia: 15 pts (6%)
Diarrhea: 213 pts (86%)
Phase II (71) (ASCEND-2),  
140 patients
ALT: 24 pts (17.1%), nausea: 9 pts (6.4%),  
diarrhea: 9 pts (6.4%), fatigue: 9 pts (6.4%),  
dyspnea: 8 pts (5.7%), AST: 7 pts (5%)
Nausea: 114 pts (81.4%)
Phase II (72) (ASCEND-3),  
124 patients
Gamma-GT: 23 pts (18.5%); ALT: 19 pts (15.3%);  
AST: 9 pts (7.3%)
Diarrhea: 102 pts (82.3%)
Alectinib 
(CH5424802, 
RO5424802)
Phase I/II (73) (AF-001JP),  
phase II portion, 46 patients
Neutropenia: 2 pts (4%); CPK: 2 pts (4%) Dysgeusia: 14 pts (30%) 
Phase I/II (74) (AF-002JG),  
dose escalation, 47 patients
Gamma-GT: 2 pts (4%); neutropenia: 2 pts (4%); 
hypophosphatemia: 2 pts (4%)
Fatigue: 14 patients (30%)
Phase II (75) (NP28761),  
86 patients
CPK: 7 pts (8%); ALT: 5 pts (6%); AST: 4 patients (5%) Constipation: 31 pts (36%)
Phase II (76) (NP28673),  
136 patients
Dyspnea: 4 pts, 3%; ALT: 2 pts (2%); AST: 2 pts (2%) Constipation: 45 pts (33%)
Brigatinib  
(AP26113)
Phase I/II (77) (NCT01449461), 
137 patients
Lipase: 12 pts (9%); dyspnea: 9 pts (7%);  
pneumonia: 8 pts (6%); fatigue: 6 pts (4%);  
hypoxia: 7 pts (5%); amylase: 6 pts (4%)
Nausea: 71 pts (52%)
Lorlatinib  
(PF-06463922)
Phase I/II (78), dose escalation 
(NCT01970865), 45 patients
Hypercholesterolemia: 5 pts (11%) Hypercholesterolemia: 26 
pts (59%)
Entrectinib  
(RXDX-101)
Phase I (112) (ALKA-372-001),  
38 patients
Asthenia (DLT): 2 pts (5.3%);  
muscular weakness (DLT): 2 pts (5.3%)
Paresthesia: 16 pts (42%)
Phase I/IIa (113) (STARTRK-1),  
27 patients 
Neutropenia (DLT): 3 pts (11%); fatigue (DLT): 2 pts (7%); 
cognitive impairment (DLT): 2 pts (7%)
Fatigue: 9 pts (33%)
ALK, anaplastic lymphoma kinase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; gamma-GT, gamma-glutamyl-
transpeptidase; CPK, creatine-phosphokinase; DLT, dose-limiting toxicity. 
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With respect to ceritinib, in the expansion cohort of 
the phase I trial (ASCEND-1) the most frequent all-grade 
toxicity was diarrhea, which occurred in 213 out of 255 
patients (86%); nausea was reported in 205 cases (83%) (70). 
The most common grade 3–4 laboratory abnormalities 
were increased alanine aminotransferase [73 (30%) patients] 
and increased aspartate aminotransferase [25 (10%)] (70). 
Concerning the phase II study ASCEND-2, conducted in 
patients who underwent chemotherapy and crizotinib, the 
most common all-grade toxicity was nausea, occurring in 
114 patients (81.4%); increased ALT (24 patients, 17.1%), 
nausea (9 patients, 6.4%), diarrhea (9 patients, 6.4%), 
fatigue (9 patients, 6.4%), dyspnea (8 patients, 5.7%), and 
AST elevation (7 patients, 5%) were the most frequent 
grade 3–4 events (70). Diarrhea (102 patients, 82.3%) 
was the most common all-grade toxicity in the phase 
II study ASCEND-3, conducted in patients naive from 
ALK inhibitors; in this trial, elevated gamma-glutamyl-
transpeptidase (gamma-GT, 23 patients, 18.5%), ALT 
(19 patients, 15.3%) and AST (9 patients, 7.3%) were the 
most frequent grade 3–4 events (72).
In the phase I study of alectinib carried out in United 
States, fatigue (occurring in 14 patients, 30%) was the 
most common all-grade toxicity, while elevated gamma-
GT (2 patients, 4%), neutropenia (2 patients, 4%), and 
hypophosphataemia (2 patients, 4%) were the most 
frequent grade 3–4 events (74). In the USA phase II study 
NP28761, constipation (31 patients, 36%) represented the 
most common all-grade toxicity, and increase in creatine-
phosphokinase (CPK; 7 patients, 8%), ALT (5 patients, 6%), 
and AST (4 patients, 5%) levels were the most frequent 
grade 3–4 events (75). In the global phase II study NP28763, 
constipation (45 patients, 33%) represented the most 
common all-grade toxicity; dyspnea (4 patients, 3%); ALT 
(2 patients, 2%), and AST (2 patients, 2%) elevations were 
the most frequent grade 3–4 events (76).
With regards to brigatinib, the most common treatment-
emergent, all-grade adverse events, included: nausea (52%, 
71/137 patients), diarrhea (42%), fatigue (42%), headache 
(33%), cough (32%) (77). Early-onset pulmonary events, 
observed ≤7 days after starting treatment, included dyspnea, 
hypoxia, or new pulmonary opacities on chest computed 
tomography suggestive of pneumonia or pneumonitis and 
occurred in 11/137 (8%) patients (77). The occurrence of 
pulmonary events was remarkably less frequent with lower 
starting doses of the drug. As these early lung features are 
unique to brigatinib, they represent a drug- and not a class-
related toxicity, requiring clinical attention to be detected 
and treated as soon as possible.
In the phase I/dose escalation study of lorlatinib, 
hypercholesterolemia represented the most common all-
grade (32 patients, 64%) and grade 3–4 (5 patients, 10%) 
adverse event (78). Although almost completely accounting 
for grade 1–2 toxicities, CNS effects (neurologic and 
psychiatric disorders affecting the state of consciousness) 
and peripheral neuropathy, occurring in 28% to 36% of 
patients, require a prompt management, which allows 
symptoms regression (78). 
With regard to entrectinib, paresthesia (16 patients, 
42%) represented the most common all-grade toxicity in the 
phase I study ALKA-372-001 conducted in solid tumors in 
general, while asthenia, the dose-limiting toxicity (DLT) in 
2 patients (5.3%) and muscular weakness (DLT in 2 patients, 
5.3%) were the most frequent grade 3–4 events (112). In the 
twin study STARTRK-1, fatigue (nine patients, 33%) was 
the most common all-grade toxicity, with neutropenia (DLT 
in three patients, 11%), fatigue (DLT in two patients, 7%) 
and cognitive impairment (DLT in two patients, 7%) being 
the most frequent grade 3–4 events (113). 
Positioning in clinical practice
A few years ago, the availability of crizotinib made ALK-
positive patients the second subgroup of advanced NSCLC 
eligible for treatment with a targeted drug in clinical 
practice, following the introduction of Epidermal Growth 
Factor receptor (EGFR) tyrosine kinase inhibitors for 
EGFR-mutations positive cases. Despite the major clinical 
improvement determined by the introduction of crizotinib, 
all treated patients, after a variable duration of clinical 
benefit, experience disease progression and need further 
treatment approaches. 
Even before the results  of  the PROFILE 1014 
trial, which demonstrated the superiority of crizotinib 
compared with platinum-based chemotherapy as first-
line treatment for ALK-positive patients (13), most experts 
were convinced of the opportunity of using crizotinib as 
first-line treatment. Regardless of the line of treatment 
crizotinib is administered, the most challenging therapeutic 
decisions come when progression to the compound 
occurs, in terms of both the correct definition of crizotinib 
failure and of the selection of proper treatment. When 
other targeted agents were not yet available, patients 
with disease progression on crizotinib, if eligible for 
further treatment, could remain on crizotinib “beyond 
progression”, or were switched to chemotherapy (114). 
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In patients with frank disease progression, this latter strategy 
was a clinically sound approach. On the other hand, for 
patients experiencing progression in a single site or in a few 
disease sites (the so called “oligo-progressive diseases”), 
continuation of crizotinib, alone or associated with local 
therapy (surgery and/or ablative treatments), has been 
commonly proposed as a reasonable option (103,109,115).
In the last years, many patients treated with crizotinib 
have received this drug beyond progression. In the phase 
I trial, 56.5% of progressive patients were still obtaining 
clinical benefit according to investigators’ opinion and 
continued crizotinib, in some cases for a long period (63). 
Similarly, in the phase III trial comparing crizotinib versus 
chemotherapy (docetaxel or pemetrexed) as second-
line treatment (11), many patients continued crizotinib 
beyond documented progression, with a median duration 
of further treatment of 16 weeks (range, 3–73 weeks). In 
a retrospective analysis of two single-arm trials, in which 
patients who developed disease progression according 
to RECIST criteria were allowed to continue treatment 
with crizotinib if they were still obtaining clinical benefit, 
overall survival from progression was significantly longer 
for patients who continued crizotinib than for those who 
stopped the drug (16.4 vs. 3.9 months; HR 0.27, 95% 
CI, 0.17–0.42; P<0.0001) (116). Based on these data, the 
possibility of continuing crizotinib is discussed in NCCN 
guidelines as an option for patients with asymptomatic 
progression but also, together with local therapy, for 
patients with symptomatic brain lesions (isolated or 
multiple) or with isolated systemic lesions (108). However, 
it should be considered that the results discussed above 
with the “beyond progression” strategy are clearly affected 
by selection bias. Although supporting the feasibility and 
the acceptable tolerability of a prolonged administration 
of crizotinib, they do not provide robust evidence of the 
efficacy of this treatment strategy. 
Of note, the South West Oncology Group is conducting 
a randomized phase II trial (SWOG 1300; ClinicalTrials.
gov identifier: NCT02134912) testing the role of 
continuing crizotinib beyond progression in addition to 
chemotherapy. In this trial, patients assigned to the control 
arm receive pemetrexed alone, while patients assigned to 
the experimental arm receive crizotinib plus pemetrexed. 
This trial likely will not add evidence on the efficacy of 
pemetrexed in this setting, given that both arms receive this 
drug, but will add prospective, randomized evidence about 
the use of crizotinib beyond progression. 
The availability of second- and third-generation ALK 
inhibitors in clinical practice has and will hopefully assume 
a relevant impact in the therapeutic choices for patients 
experiencing disease progression on crizotinib as well as 
for crizotinib-naive patients. For the former population of 
patients, the treatment algorithm is now clearly enriched 
by the development of novel-generation ALK inhibitors. 
The use of these new agents is associated with high 
clinical activity in this setting. To date, ceritinib is the only 
treatment approved both by FDA and EMA, as another line 
of treatment to overcome crizotinib-resistant tumors. 
Among the different clinical presentation of patients with 
ALK rearrangement, the activity of ceritinib (and, more in 
general, of second-generation ALK inhibitors) is particularly 
appealing in patients with brain metastases, frequently 
present either at diagnosis of advanced disease or as lesions 
accounting for disease progression. Although crizotinib 
is active also in these patients, progression of preexisting 
intracranial lesions, or development of new lesions while on 
treatment with crizotinib is very common. In these subjects, 
the availability of a treatment that has shown a good activity 
on brain metastases assumes a great clinical value. 
It must be observed that the onset of ALK resistance is a 
heterogeneous process: target mutations, amplifications and 
bypasses are proven mechanisms of resistance (14,15). For 
this reason, the rational choice of the optimal ALK inhibitor 
after progression to crizotinib (the same concept is applicable 
to progression to novel compounds) is of crucial importance 
and should be guided by the particular molecular events 
detected at disease relapse when re-biopsies are envisageable. 
Treatment can be oriented by preclinical evidence of drug 
activity when mutations in the ALK kinase domain occur 
(66,93). As explained for brigatinib, its double activity upon 
ALK and EGFR signaling could be useful when the second 
is involved in resistance mechanisms. The recently reported 
activation of c-MET, HER-3 and IGF-1R pathways in 
alectinib-resistant ALK-rearranged cells lines rise the issue of 
combined molecular treatments addressing to tumor-tailored 
biologic alterations (117). The latter concept has already 
been approached in in vitro pharmacological screens (118) 
and could be applicable in ALK-positive tumors where 
KRAS activation is the putative responsible of treatment 
resistance and clinical progression, with the putative double 
blockade (ALK and MEK inhibition) in a melanoma-
oriented fashion. 
Sequential or combinatorial treatments with ALK 
inhibitors and immune checkpoints inhibitors, targeting the 
programmed cell death receptor and its ligand (PD-1 and 
PD-L1, respectively) as well as the cytotoxic T-lymphocyte-
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associated antigen 4 (CTLA-4) are in current clinical 
study (ClinicalTrials.gov identifiers: NCT01998126, 
NCT02393625, NCT02584634). Nevertheless, the 
substantial lack of high mutational rates in ALK-rearranged 
NSCLC, due also to the scarce tobacco exposure of ALK-
positive patients, makes less probable a substantial benefit 
derivable from immune-releasing compounds (119), as seen 
for EGFR-mutated tumors (120,121) and emerged from 
retrospective series (122).
Heat shock protein 90 (HSP90) inhibitors could have 
a potential role in treating crizotinib-resistant patients, 
but mono-therapy has been studied with results indicating 
inferior ORR and less-tolerable toxicity profile, as well as 
poor CNS activity compared with ALK inhibitors. These 
drugs are currently under evaluation in combination with 
ALK inhibitors, postulating the synergistic effect of direct 
kinase inhibition and disruption of cell signaling (123,124). 
Nevertheless, the outstanding activity of novel ALK 
inhibitors, as well as their sub-optimal toxicity profiles, 
does not allow to allocate HSP90 combinations among the 
plausible future breakthrough for the treatment of ALK-
positive patients. 
An intriguing combination, suggested by the reported 
interplays between ALK signaling and hypoxia-inducible 
factors, is on the other and represented by combination of 
alectinib and the anti-angiogenic antibody bevacizumab 
(ClinicalTrials.gov identifier: NCT02521051).
With respect to the possibility to use second-generation 
ALK inhibitors, like ceritinib and alectinib, in crizotinib-
naïve patients, it can be argued that these novel agents 
generally show more than 10-fold higher potency against 
the ALK-rearranged protein with a wild-type ALK kinase 
domain (66,84,86,93) and display increased affinity for 
second-site mutated ALK. Potentially, second-generation 
ALK inhibitors, compared with crizotinib, may offer an 
improved duration of response with a delay in the onset 
of ALK resistance and a treatment option available for 
secondary mutation-dependent resistance. These two 
concepts should be translated in new treatment paradigms. 
In fact, taking into consideration that crizotinib is a 
relatively weak ALK-inhibitor in NSCLC lines carrying an 
EML4-ALK fusion gene compared to novel compounds, 
the prescription of the new molecules in crizotinib-naïve 
patients can be envisaged. However, in the next future, the 
administration of crizotinib as first-line treatment (which 
was the “backbone” of all the therapeutic decisions discussed 
above) could be challenged by the results of the trials 
currently testing second-generation ALK inhibitors in the 
same setting. If the randomized phase III trial comparing 
ceritinib and cisplatin or carboplatin plus pemetrexed 
(ClinicalTrials.gov identifier: NCT01828099) will lead to 
positive results, ceritinib could represent an alternative to 
crizotinib as first-line option. The study completion date 
is estimated in June 2018. The selection among different 
drugs will be likely based on indirect comparison of activity 
and toxicity. Furthermore, also alectinib is currently tested 
as first-line treatment, in a head-to-head comparison versus 
crizotinib (ClinicalTrials.gov identifier: NCT02075840): 
the estimated study completion date is December 2017. The 
anticipation of the impressive activity of front-line alectinib 
in the Japanese cohort has already been mentioned (85) 
and, if preliminary results will be confirmed, the scenario of 
ALK inhibitions in NSCLC will ostensibly change. 
As previously approached, the results of these trials will 
require a critical interpretation beyond the assumption 
of their eventual positivity. If crizotinib treatment can 
be usefully followed by next-generation molecules, the 
inverse therapeutic sequence cannot be envisaged, with 
the exception of only one case reported worldwide so 
far (95). Novel molecules administered as upfront ALK 
inhibitors should therefore allow disease control periods 
at least comparable to experienced crizotinib-based 
sequences. Moreover, mechanisms of resistance to the 
second- and third-generation ALK inhibitor are up to now 
clearly defined and seem to differ from events leading to 
crizotinib exhaustion (95,125). From this point of view, the 
administration of the novel compounds as the first ALK-
directed approach could leave physicians “molecularly 
unarmed” at the moment of disease progression. Besides 
the precious contributions of trails evaluating novel ALK 
inhibitors in ALK-TKI naïve patients, studies prospectively 
comparing sequences of targeted treatments versus next-
generation compounds upfront could be particularly useful. 
The wide range of ALK inhibitors, an extremely 
precious resource, helps to emphasize the concept that 
ALK-positive patients should be maintained under specific 
targeted inhibition as long as possible. Beyond-progression 
strategies, local treatment for oligometastatic disease 
and SNC progression, eventual tailored-inhibition re-
challenges, as well as optimal treatment sequences based on 
the mechanism of biological resistance, should be optimally 
integrated in every single patient. 
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